Atara Biotherapeutics’ (ATRA) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of Atara Biotherapeutics (NASDAQ:ATRA) in a report published on Wednesday morning,Benzinga reports. HC Wainwright also issued estimates for Atara Biotherapeutics’ Q4 2024 earnings at ($5.20) EPS, FY2024 earnings at ($11.46) EPS, Q1 2025 earnings at ($4.35) EPS, Q2 2025 earnings at ($4.15) EPS, Q3 2025 earnings at $3.35 EPS, Q4 2025 earnings at ($3.90) EPS and FY2025 earnings at ($9.08) EPS.

Other research analysts also recently issued reports about the company. Rodman & Renshaw initiated coverage on Atara Biotherapeutics in a research note on Friday, December 20th. They issued a “buy” rating and a $25.00 price target for the company. RODMAN&RENSHAW raised shares of Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, December 20th. TD Cowen raised shares of Atara Biotherapeutics to a “strong-buy” rating in a research report on Friday, November 29th. Finally, Canaccord Genuity Group decreased their price objective on shares of Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $17.75.

Atara Biotherapeutics Trading Up 18.6 %

Shares of ATRA opened at $8.22 on Wednesday. The stock has a market capitalization of $47.35 million, a price-to-earnings ratio of -0.32 and a beta of 0.51. Atara Biotherapeutics has a 12 month low of $5.40 and a 12 month high of $39.50. The firm has a fifty day simple moving average of $11.97 and a 200 day simple moving average of $9.96.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, topping analysts’ consensus estimates of ($3.77) by $0.84. The business had revenue of $40.19 million for the quarter, compared to analyst estimates of $23.00 million. During the same quarter in the prior year, the company earned ($16.50) earnings per share. As a group, research analysts predict that Atara Biotherapeutics will post -9.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Atara Biotherapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its position in shares of Atara Biotherapeutics by 9.5% in the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after purchasing an additional 4,043 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in Atara Biotherapeutics in the 2nd quarter valued at $53,000. FMR LLC lifted its position in shares of Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 7,381 shares during the period. State Street Corp grew its holdings in shares of Atara Biotherapeutics by 52.3% during the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 7,680 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Atara Biotherapeutics in the second quarter worth $79,000. 70.90% of the stock is owned by institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.